Monday, 28th November 2022
<To guardian.ng
Search
Breaking News:

NAFDAC appoints new acting DG, Monica Eimunjeze

By Chukwuma Muanya
21 November 2022   |   4:01 am
Director, Registration and Regulation Affairs, Dr. Monica Hemben Eimunjeze, has been appointed at Acting Director General of the National Agency for Food and Drug Administration and Control (NAFDAC).

NAFDAC

Director, Registration and Regulation Affairs, Dr. Monica Hemben Eimunjeze, has been appointed at Acting Director General of the National Agency for Food and Drug Administration and Control (NAFDAC).

She had previously served as Technical Assistant to the Director General of NAFDAC and as Director, Drug Evaluation and Research.

Eimunjeze has coordinated several national and international programmes to support strengthening regulatory capacity within the agency and worked on several projects to institute regulatory reform.

She has represented the agency and made presentations at several fora highlighting NAFDAC’s activities and achievements.
She graduated from Ahmadu Bello University Zaria with a Bachelor of Pharmacy in 1986 and went on to obtain a Doctor of Pharmacy from Mercer University, Atlanta, Georgia, and a Master of Science (MSc) in Biotechnology, Innovation and Regulatory Science from Purdue University.

Eimunjeze has varied experience in the pharmaceutical sector spanning different areas of practice. Her industrial exposure with GlaxoSmithKline from 1989 to 1996 saw her holding several positions, including Medical Representative, Quality Manager and Regulatory Affairs Manager.

She has attended several courses, workshops and conferences in Quality Management Systems (QMS), Clinical Trial Regulation, Good Manufacturing Practice (GMP), Biotechnology and Regulatory Affairs.

Eimunjeze currently serves as a member of the Expert Scientific Advisory Committee (ESAC) Medicines for Malaria Ventures (MMV). She is a member of the Task Team for the creation of the African Medicines Agency (AMA) and is NAFDAC’s representative at the United States Pharmacopoeia as Convention observer.